Acute Pancreatitis Market Analysis 2019 by Types of Testing (Transabdominal Ultrasound, Endoscopic Ultrasound (EUS), Magnetic Resonance Cholangiopancreatography (MRCP), Computerized Tomography (CT)), by Types of Treatment (Fluids, Nutritional Support, Treatment of Underlying Issues, Endoscopic Retrograde Cholangiopancreatography (ERCP)) – Forecast To 2022
Acute pancreatitis is an inflammatory state of the pancreas that is excruciatingly pain full and now and at times fatal. Regardless of the technological advances in critical care drugs in the course of recent years, the death rate of acute pancreatitis has stayed at around 10%. Diagnosis of pancreatic issues is regularly difficult, and medications are in this manner postponed in light of the fact that the organ is generally out of reach.
The global acute pancreatitis market is expected to grow at a CAGR of 3.5% during forecasted period 2017-2023.
Get Free Sample Copy at https://www.marketresearchfuture.com/sample_request/1565
Acute pancreatitis (AP) is a systemic immunoinflammatory response to auto-digestion of the pancreas and peri-pancreatic organs. This condition is common and life-threatening disease. With an annual incidence of 4.9–73 cases per 100000 people worldwide. The males are predominantly affected at young ages with a ratio of 2.5:1. The mortality rate for pancreatitis is between 1.5% and 4.2% according to large epidemiological studies but is a frequent gastrointestinal disease with a morbidity rate of 30% in severe cases.
Difficulty in the diagnosis of the disease due to the relative inaccessibility of the organ is a crucial challenge for the market. However, the demand for appropriately effective diagnostic and treatment options is expected to prompt more in-depth research and development of the same, thus facilitating growth and opening new avenues for opportunities in the next few years.
Akcea Therapeutics is working to confirm a path forward for WAYLIVRA (volanesorsen) in the U.S. for patients living with familial chylomicronemia syndrome (FCS), which is often accompanied by fatal acute pancreatitis. The drug has been shown to reduce the risk of acute pancreatitis in those living with FCS.
Acute Pancreatitis (AP) Market Segmentation
Segmentation of the global acute pancreatitis market has been performed by types of testing, types of treatment, types of therapy and region.
By types of testing, the market has been segmented to include Magnetic resonance cholangiopancreatography (MRCP), Computerized tomography (CT), transabdominal ultrasound, Endoscopic ultrasound (EUS), and others.
By types of treatment, the market has been divided into treatment of underlying issues, nutritional support, fluids, Endoscopic Retrograde Cholangiopancreatography (ERCP) and others.
By types of therapy, the market has been segmented to include massage therapy, therapeutic touch, acupuncture, and others.
By region, the global market has been divided into North America, Europe, the Asia-Pacific and the Middle East and Africa.
Abbott Laboratories (US), McNeil Consumer Healthcare (US), Sun BioPharma, Inc (US), Atox Bio Inc. (Israel), Calcimedica Inc. (US), D-Pharm Ltd (Israel), Dynavax Technologies Corporation (US), Glaxosmithkline Plc (UK) university’s and institutes are also included in the treatment of acute pancreatic like Radboud University, University Medicine Greifswald and others are some of the prominent players at the forefront of competition in the global acute pancreatitis market and are profiled in MRFR Analysis.
Brows Complete Premium Research at https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565
North America, with its dominating share, is expected to fuel growth for the market due to the growing incidence of acute pancreatitis and high demand for effective treatment options for the same. The region boasts a strong healthcare sector with growing expenditure on research for the development of appropriate treatment measures, thus fostering market growth.
Europe closely follows with the second most significant market share. This can be attributed to the widespread occurrence of the disease in the region. Many developed countries of the region are seeing growing diagnoses of the condition due to gallstones, while the developing economies in the region with a reputation for high alcohol consumption are responsible for increased incidences of acute pancreatitis in the region.
The Asia Pacific has a vast patient population which has rising disposable incomes in its emerging economies thus fueling demand for modern treatment options. Moreover, there is growing investment in healthcare in this region which facilitates growth further.
The Middle East and Africa are expected to show limited growth, with the low development of the medical sector in the underdeveloped countries of Africa. Growth in the region is likely to be witnessed in the Middle East and North African region where there is sufficient development of the healthcare sector.
- Acute Pancreatitis drug manufacturers
- Acute Pancreatitis drug Suppliers
- Pharmaceutical companies
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Inquire for Exclusive Discount at https://www.marketresearchfuture.com/check-discount/1565
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312